Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DAO | P14920 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 2/20 | 0.42 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | NOTUM | Q6P988 | 3/20 | 0.37 |
| ▸ | KMO | O15229 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 1/20 | 0.37 |
| ▸ | RXRB | P28702 | 1/20 | 0.37 |
| ▸ | RXRG | P48443 | 1/20 | 0.37 |
| ▸ | PYCR1 | P32322 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 2/20 | 0.35 |
| ▸ | KDR | P35968 | 2/20 | 0.35 |
| ▸ | CCR2 | P41597 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | PHGDH | O43175 | 1/20 | 0.34 |
| ▸ | FLT1 | P17948 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4084168 | 0.87 | IDO1 (0.57) | IDO1PYCR1KDR | |
| SCHEMBL584238 | 0.86 | DAO (0.52) | DAOIDO1MRGPRX4NOTUMKMO | |
| SCHEMBL6858263 | 0.82 | RXRA (0.47) | DAOIDO1NOTUMRXRARXRB | |
| SCHEMBL541099 | 0.81 | IDO1 (0.47) | DAOIDO1MRGPRX4NOTUMKMO | |
| SCHEMBL4656217 | 0.80 | DAO (0.49) | DAOIDO1MRGPRX4NOTUMKMO | |
| SCHEMBL24400227 | 0.78 | DAO (0.48) | DAOIDO1MRGPRX4NOTUMKMO | |
| SCHEMBL257057 | 0.78 | DAO (0.48) | DAOIDO1MRGPRX4NOTUMPYCR1 | |
| SCHEMBL30152373 | 0.78 | DAO (0.48) | DAOIDO1NOTUM | |
| SCHEMBL3637724 | 0.78 | KIF11 (0.51) | DAORXRARXRBRXRGKIF11 | |
| SCHEMBL1592495 | 0.78 | DAO (0.48) | DAOIDO1MRGPRX4NOTUMKMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025024030-A2 | MOLECULAR GLUES TARGETING A TRANSCRIPTIONAL REGULATOR OF ABERRANT METABOLIC STATES | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-30 | — | — | WO | disclosed |
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2021236885-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2021-11-25 | — | — | WO | disclosed |
| EP-1554253-A4 | IMIDAZOLIUM CXCR3 INHIBITORS | SMITHKLINE BEECHAM CORP (US) | 2006-09-20 | — | — | EP | disclosed |
| EP-1554253-A1 | IMIDAZOLIUM CXCR3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2005-07-20 | — | — | EP | disclosed |
| WO-2003101970-A1 | IMIDAZOLIUM CXCR3 INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192644-A1 | PIPERIDINE-2,6-DIONES AS SMALL MOLECULE DEGRADERS OF HELIOS AND METHODS OF USE | IKZF2, IKZF1, NUTF2 | DAO 3563/4885IDO1 992/4885MRGPRX4 4556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.